Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases under 4 years of age, and carried out histologic review, methylation profiling,...
Saved in:
Published in | Cancer discovery Vol. 10; no. 7; pp. 942 - 963 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.07.2020
|
Subjects | |
Online Access | Get full text |
ISSN | 2159-8274 2159-8290 2159-8290 |
DOI | 10.1158/2159-8290.CD-19-1030 |
Cover
Summary: | Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases under 4 years of age, and carried out histologic review, methylation profiling, and custom panel, genome, or exome sequencing. After excluding tumors representing other established entities or subgroups, we identified 130 cases to be part of an "intrinsic" spectrum of disease specific to the infant population. These included those with targetable MAPK alterations, and a large proportion of remaining cases harboring gene fusions targeting
(
= 31),
(
= 21),
(
= 9), and
(
= 4) as their driving alterations, with evidence of efficacy of targeted agents in the clinic. These data strongly support the concept that infant gliomas require a change in diagnostic practice and management. SIGNIFICANCE: Infant high-grade gliomas in the cerebral hemispheres comprise novel subgroups, with a prevalence of
, or
gene fusions. Kinase fusion-positive tumors have better outcome and respond to targeted therapy clinically. Other subgroups have poor outcome, with fusion-negative cases possibly representing an epigenetically driven pluripotent stem cell phenotype.
.
. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Authors’ Contributions Study supervision: M. Zuckermann, D.W. Ellison, T.S. Jacques Other (involved in histology): A. Avery Writing, review, and/or revision of the manuscript: M. Clarke, A. Mackay, B. Ismer, R.G. Tatevossian, T.A. Bale, K.M. Kurian, J. Knipstein, U. Schüller, U. Kordes, D.E. Kram, M. Snuderl, L. Bridges, A.J. Martin, B. Zebian, J.K.R. Boult, S.P. Robinson, I.J. Dunkel, T.J. MacDonald, M. Preusser, R. Packer, H.-K. Ng, M.D. Wood, M.A. Davare, P. Brandal, M. Farrell, J. Schittenhelm, M.U. Schuhmann, M. Ebinger, W.N.M. Dinjens, T. Pietsch, P.H. Driever, B.C. Worst, D. Sturm, O. Witt, G.S. Colafati, S. Bailey, A.S. Moore,T.E.G. Hassall, S.P. Lowis, D.S. Ziegler, M.A. Karajannis, D.R. Hargrave, F. Carceller, L.V. Marshall, A. von Deimling, C.M. Kramm, S.M. Pfister, M. Vinci, D. Capper, S. Popov, D.W. Ellison, T.S. Jacques, D.T.W. Jones, C. Jones Other (manuscript critical reading/writing): F. Andreiuolo Other (reference pathology): T. Pietsch Conception and design: A. Mackay, M. Snuderl, R. Packer, L. Baird, T.S. Jacques, D.T.W. Jones, C. Jones Other (histopathologic examination of tumor samples): F. Diomedi-Camassei Development of methodology: M. Clarke, B. Ismer, E. Izquierdo, D.M. Carvalho, A. Virasami, R. Packer, A. von Deimling, S.M. Pfister, M. Vinci, D.T.W. Jones Other (helped source archival tissue): T. Bloom Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.C. Pickles, I. Stoler, S. Temelso, A. Burford, A.R. Fairchild, A. Avery, K. Haupfear, J.D. Dalton, K.M. Kurian, J. Schittenhelm, T. Pietsch, L. Hiddingh, C. Mitchell, C.M. Kramm, D.W. Ellison Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Clarke, A. Mackay, Ismer, S. Newman, T.A. Bale, E. Izquierdo, D.M. Carvalho, V. Molinari, A. Burford, L. Howell, J. Wen, M. Snuderl, M. Sill, R. Packer, D.A. Solomon, W.N.M. Dinjens, T. Pietsch, A. Korshunov, D. Sturm, G.S. Colafati, F. Diomedi-Camassei, M.J. Cowley, D.S. Ziegler, F. Carceller, S.M. Pfister, F. Sahm, S.J. Baker, D. Capper, S. Popov, D.W. Ellison, T.S. Jacques, D.T.W. Jones, C. Jones Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Clarke, B. Ismer, J.C. Pickles, R.G. Tatevossian, S. Newman, T.A. Bale, I. Stoler, D.M. Carvalho, V. Molinari, A. Burford, L. Howell, A. Virasami, J. Chalker, M. Kristiansen, W. Orisme, M. Hubank, K.M. Kurian, C. Rowe, M. Maybury, S. Crosier, J. Knipstein, U. Schüller, U. Kordes, D.E. Kram, M. Snuderl, L. Bridges, A.J. Martin, L.J. Doey, S. Al-Sarraj, C. Chandler, B. Zebian, C. Cairns, R. Natrajan, J.K.R. Boult, S.P. Robinson, I.J. Dunkel, S.W. Gilheeney, M.K. Rosenblum, D. Hughes, P.Z. Proszek, T.J. MacDonald, M. Preusser, C. Haberler, I. Slavc, H.-K. Ng, S. Caspi, M. Popovic, B.F. Kotnik, M.D. Wood, L. Baird, D.A. Solomon, T.K. Olsen, P. Brandal, M. Farrell, J.B. Cryan, M. Karremann, M.U. Schuhmann, M. Ebinger, W.N.M. Dinjens, K. Kerl, S. Hettmer, T. Pietsch, P.H. Driever, A. Korshunov, B.C. Worst, D. Sturm, E. Miele, G.S. Colafati, S. Bailey, A.S. Moore, T.E.G. Hassall, S.P. Lowis, M. Tsoli, M.J. Cowley, D.S. Ziegler, M.A. Karajannis, K. Aquilina, D.R. Hargrave, F. Carceller, L.V. Marshall, A. von Deimling, C.M. Kramm, S.M. Pfister, F. Sahm, S.J. Baker, A. Mastronuzzi, Carai, M. Vinci, D. Capper, S. Popov, D.W. Ellison, T.S. Jacques, D.T.W. Jones |
ISSN: | 2159-8274 2159-8290 2159-8290 |
DOI: | 10.1158/2159-8290.CD-19-1030 |